Ginsenoside Rd monomer alleviates ulcerative colitis by inhibiting microRNA of macrophages

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500112229

Enrollment

Unknown

Registered

2025-11-11

Start date

2025-11-20

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

active-stage ulcerative colitis group:None

remission ulcerative colitis patients:None

Colorectal Cancer Group:None

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: UC patients aged 18-60 years old. The patients was diagnosed by symptoms, endoscopy, CTE and pathology.

Exclusion criteria

Exclusion criteria: Patients who suffered immune disease ,severe cardiopulmonary disease, severe coagulation disorder, taken anticoagulants and anti-platelet drugs within 1 week.

Design outcomes

Primary

Measure	Time frame
NFa;IL-6;IFN?;IL-12/23p40;IL-10;TGF-ß;CD68;CD206;CD40;CD163;CD83;CD11c;MHC-?(I-Ab);HLA-DRB1;HLA-DRB3;HLA-DRB4;HLA-DRB5;CD1a;	—

Countries

China

Contacts

Public ContactBo Qu

The 2nd Affiliated Hospital of Harbin Medical University

qubo_1970@hotmail.com+86 130 3003 9874

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026